Dr. Mahmoud Ghazzi Named Global Head of Drug Development at Daiichi Sankyo

Dr. Mahmoud Ghazzi Named Global Head of Drug Development at Daiichi Sankyo

Parsippany, NJ, January 21, 2014 – Daiichi Sankyo announced that Mahmoud Ghazzi MD, PhD has been appointed Global Head of Drug Development at Daiichi Sankyo.   In this role Dr. Ghazzi is responsible for the oversight of all drug development related activities for the global organization.  Dr. Ghazzi also will maintain his existing role as Head of the Americas Region for DSPD. 

"Daiichi Sankyo is dedicated to developing treatments for unmet medical needs," said Dr. Ghazzi.  "I am proud to be part of an organization that has built a reputation on providing patients with high quality, innovative therapies that address significant health issues.  I look forward to leading a global team of talented people who are dedicated to developing innovative medicines."

Dr. Ghazzi joined Daiichi Sankyo in August 2011 as Executive Vice President of Drug Development for the Americas Region. Since then, he has made significant contributions to the company's development strategy and portfolio planning, taking on increasing levels of accountability.   Previously, Dr. Ghazzi served in numerous roles in the healthcare industry with GlaxoSmithKline and Pfizer where he developed and managed clinical trials for cardiovascular, metabolism, obesity and diabetes medications.

Following the completion of his medical education from Damascus University, Dr. Ghazzi completed a master's degree in Public Health and a PhD in Biomedical Engineering from University of Michigan in Ann Arbor.  He then joined the faculty of The University of Michigan Reproductive Sciences Program and was the recipient of several grants and awards, including a National Institutes of Health Physician Scientist award.

About Daiichi Sankyo

Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients in both mature and emerging markets. While maintaining its portfolio of marketed pharmaceuticals for hypertension, hyperlipidemia, and bacterial infections, the Group is engaged in the development of treatments for thrombotic disorders and focused on the discovery of novel oncology and cardiovascular-metabolic therapies. Furthermore, the Daiichi Sankyo Group has created a "Hybrid Business Model," which will respond to market and customer diversity and optimize growth opportunities across the value chain. For more information, please visit: www.daiichisankyo.com.

Daiichi Sankyo, Inc., headquartered in Parsippany, New Jersey, is a member of the Daiichi Sankyo Group.  For more information on Daiichi Sankyo, Inc., please visit www.dsi.com.

CONTACT

Marah Oberfield

Public Affairs

973-944-2253

[email protected]

Suggested Articles

Researchers are studying the retrovirus KoRV-A, which is spreading among koalas, to gain new insights into how DNA evolves.

Shionogi and Hsiri Therapeutics first joined forces last year in a licensing and R&D deal focused on tuberculosis and non-tuberculous lung infections.

The efficacy results suggest the experimental oral therapy, abrocitinib, has a shot at challenging the blockbuster biologic incumbent.